San Francisco, 21 April 2030: The Report Monocyte Activation Test Market Size, Share & Trends Analysis Report By Product (MAT Kits, Reagents), By Source (PBMC Based, Cell Line Based), By Application, By End-use, By Region, And Segment Forecasts, 2025 - 2030

The global monocyte activation test market size is expected to reach USD 1.45 billion by 2030, registering a CAGR of 15.9% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is driven by several key factors. Increasing regulatory pressure to replace animal testing with more ethical, human-relevant in vitro methods is a major driver. MAT’s ability to provide accurate pyrogen detection using human immune cells makes it an attractive alternative to traditional endotoxin tests. The growing demand for biologics, vaccines, and complex pharmaceuticals further fuels MAT adoption, as safety is critical in these products. Additionally, advancements in biotechnology and the increasing emphasis on patient safety and quality control in drug development are contributing to the market's growth.

Technological innovations are significantly driving the growth of the Monocyte Activation Test (MAT) market. One of the key advancements is the development of more efficient and reproducible cell culture systems, particularly the use of immortalized human cell lines like THP-1 and U937 cells. These cell lines enhance the accuracy and consistency of MAT, making it a more reliable alternative to traditional animal testing methods. The ability to simulate the human immune response with these cell lines has improved the sensitivity of MAT, allowing for better detection of pyrogens, including both endotoxins and non-endotoxins.

Another innovation is the automation of MAT processes, which has streamlined testing workflows and reduced the time required to obtain results. Automated systems for preparing and analyzing MAT samples have increased throughput, making it more feasible for large-scale pharmaceutical and biotechnology companies to incorporate MAT into their quality control processes. Minerva Biolabs' next-generation MAT system, the NAT-MAT, represents a significant advancement in pyrogen testing. By utilizing digital PCR to measure the gene expression of IL-1β and TNF-α, the NAT-MAT provides highly sensitive and reliable results for detecting both endotoxin and non-endotoxin pyrogens. This system is optimized for fast testing, making it suitable for in-process control and final release testing of medicinal products, in line with Ph. Eur. 2.6.30 standards.

The key innovation in the NAT-MAT® lies in the parallel measurement of two cytokines alongside a housekeeping gene, which improves the accuracy of results. The housekeeping gene serves a dual purpose: it acts as a quality control for both the extraction process and cell density, ensuring the assay functions reliably across different cell densities. Additionally, the automated analysis through Minerva Biolabs' specialized software streamlines the process, ensuring compliance with regulatory requirements while enhancing testing efficiency.

This technology provides a significant improvement over traditional pyrogen testing methods by offering a more comprehensive and precise approach to ensuring the safety of pharmaceutical and biotechnological products. For example, companies like Lonza Group and Charles River Laboratories have integrated advanced cell culture technologies and automated systems into their MAT offerings, improving efficiency and scalability. Furthermore, advancements in high-throughput screening technologies have enabled faster and more cost-effective pyrogen testing, allowing MAT to be used in drug development and vaccine production more widely. These technological innovations continue to enhance MAT’s adoption, making it an essential tool for ensuring the safety and efficacy of pharmaceutical and biotechnological products.

Request sample report of Monocyte Activation Test Market@ https://www.grandviewresearch.com/industry-analysis/monocyte-activation-test-market-report/request/rs1

The market is driven by the growing need for safer pharmaceutical products and the rising adoption of in-vitro alternatives to animal testing. Regulatory support, including endorsements by organizations like the FDA and European Pharmacopeia, has boosted monocyte activation test (MAT) adoption. Increasing awareness about ethical testing methods and advancements in MAT technology are notable trends. The market is also influenced by the rising prevalence of chronic diseases and biologics development, necessitating accurate pyrogen detection. Technological innovations and collaborations further enhance market growth, addressing industry demand for reliability and precision.

The Monocyte Activation Test (MAT) has emerged as a dependable, sustainable, and animal-free method for detecting both endotoxin and non-endotoxin pyrogens (NEPs). It is validated to identify pyrogenic contaminants by activating human monocytes, which release endogenous mediators like IL-6. Compared to traditional methods such as the Rabbit Pyrogen Test (RPT), MAT offers a more ethical and efficient alternative for pyrogen detection. Regulatory support, including its inclusion in the European Pharmacopoeia (Ph. Eur. 2.6.30) and ongoing efforts to phase out RPT, has significantly boosted its adoption in pharmaceutical and medical device industries.

Conventional MAT assays employ Peripheral Blood Mononuclear Cells (PBMCs) and rely on ELISA readouts. However, these methods face challenges such as lot-to-lot variability, extended assay times, and labor-intensive processes. To overcome these limitations, innovative solutions like the LumiMAT™ assay have been developed. The LumiMAT system incorporates a luciferase reporter gene to detect activated NF-κB protein, enabling rapid and highly sensitive pyrogen detection. By eliminating the need for ELISA and serum-based components, LumiMAT reduces reaction times and ensures consistent results. These advancements are accelerating the adoption of MAT in industries that require precise and efficient pyrogen detection methods.

The European Pharmacopoeia Commission (EPC) has taken significant steps to eliminate the Rabbit Pyrogen Test (RPT) by July 2030, mandating the use of in vitro methods like MAT for pyrogen testing. This transition aligns with sustainability goals and reflects industry trends toward more ethical testing practices. MAT’s ability to assess human inflammatory responses ensures the safety, efficacy, and quality of drugs, vaccines, and medical devices, making it a preferred choice for manufacturers. The updated guidelines emphasize risk-based assessments and standardized methodologies, facilitating MAT’s integration into routine quality control processes.

Innovative systems like the PyroCell MAT System by Lonza Bioscience are transforming the MAT market. Developed in partnership with Sanquin Reagents B.V., this system uses cryopreserved PBMCs, eliminating the need for donor qualification and cell isolation. The ready-to-use PyroCell system ensures on-demand availability, supporting pharmaceutical and biologics manufacturers in product development and release. It is particularly effective for detecting pyrogens in complex formulations like vaccines and cell-based biologics. By providing sensitive, reliable pyrogen detection without the use of experimental animals, PyroCell aligns with sustainability objectives and reinforces MAT’s role as a leading solution for pyrogen testing.